Citius Oncology, Inc.

NASDAQ: CTOR · Healthcare · Medical - Pharmaceuticals

PublicHQ New York City, NY · New YorkCIK 0001851484Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 57DQ —GM —SS 49

v0.1 · 35/100 weight · pillars only

↑ workforce scale, Piotroski F · ↓ listing tenure, filing timeliness

Methodology →

Revenue TTM

$7.1M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$24.8M

Employees

285

as of 2026-08-19

Market cap

$65.4M

as of 2026-08-19

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$24.8M-$24.8M2025

Operating income-$23.5M-$23.5M2025

Total assets$100.9M$100.9M2025

Liabilities$56.1M$56.1M2025

Equity$44.9M$44.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Citius Oncology, Inc.’s financial profile?

Citius Oncology, Inc. earned -$24.8M in FY2025 net income.

Peers · Healthcare

Instinct Bio Technical Co. Holdings Inc.——PMV Pharmaceuticals, Inc.——OS Therapies Incorporated——Atlantic International Corp——Boundless Bio, Inc.——MindWalk Holdings Corp.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOLeonard L. Mazur

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersNew York City, NY

ExchangeNASDAQ: CTOR

Employees285

IPO date2022-12-08

Latest filings

DEF 14A2026-08-26 8-K2026-08-14 10-Q2026-08-14 8-K2026-08-12 8-K2026-08-05 8-K2026-06-01 10-Q2026-05-15 8-K2026-05-15

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.